Abstract

Using radiolabelled peptides that bind, with high affinity and specificity, to receptors on tumour cells is one of the most promising fields in modern molecular imaging and targeted radionuclide therapy (1). In the emergence of molecular imaging and nuclear medicine diagnosis and therapy, albeit theranostic, radiolabelled peptides have become vital tools for in vivo visualisation and monitoring physiological and biochemical processes on molecular and cellular levels (2). This approach may benefit patients in the era of personalised medicine.

Highlights

  • The overexpression of numerous peptidebinding receptors in various tumours and inflammatory tissues have led to the use of radiolabelled peptides for imaging and therapy [2, 3]

  • Peptides have been labelled with indium-111 (In-111) and technetium99m (Tc-99m) for single-photon emission computed tomography (SPECT) imaging and with gallium-68 (Ga-68), copper-64 (Cu-64), yttrium-86 (Yt-86) and fluorine-18 (F-18) for positron emission tomography (PET)

  • One such is the introduction of the bifunctional chelator (BFC) suitable for complexation of 18F-fluoride bound to a metal and a functional group that allows for bioconjugation to the peptides of interest [1, 6]

Read more

Summary

Introduction

The overexpression of numerous peptidebinding receptors in various tumours and inflammatory tissues have led to the use of radiolabelled peptides for imaging and therapy [2, 3]. Peptides, which are usually non-immunogenic, possess strong tissue penetration properties and high tumour uptake leading to favourable tumour-to-background ratios for excellent image quality and tumour targeting therapy [2, 4].

Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.